gonapeptyl
PreclinicalSmall molecule
gonapeptyl is one of 46 small molecule programs targeting Endometriosis. It is currently in Preclinical.
1
Indications
2
Total Trials
1
Active Trials
45
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
57 competitors in Endometriosis
#DrugCompanyPhaseTrials
1Danocrine
SanofiApproved
Bayer Aspirin
BayerApproved
Estrace
Novo NordiskApproved
IC-Green
PProvepharm SAS
Approved
Ketalar
AAultman Health Foundation
Approved
Catapres
Boehringer IngelheimApproved
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Jadelle
IItalian Network for Tumor Biotherapy Foundation
Approved
Implanon
OOrganon and Co
Approved
Zocor
OOrganon and Co
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Endometriosis1 trial
Dienogest Versus GnRH-a Pre-treatment in Women With Endometriosis Undergoing IVF
Unknown status·—·N/A·NCT03142035·189 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for gonapeptyl. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- UUniversity Hospital, Ghent